中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
22期
165-168
,共4页
动脉粥样硬化%易损血液%纤溶酶原激活物抑制物%急性冠脉综合征
動脈粥樣硬化%易損血液%纖溶酶原激活物抑製物%急性冠脈綜閤徵
동맥죽양경화%역손혈액%섬용매원격활물억제물%급성관맥종합정
Atherosclerosis%Vulnerable blood%Plasminogen activator inhibitor-1%Acute coronary syndrome
纤溶功能减低是血液高致栓性的一个重要组成部分,常见于急性冠脉综合征患者,尤以纤溶酶原激活物抑制物(plasminogen activator inhibitor-1,PAI-1)水平升高为著。 PAI-1通过抑制纤维溶解,促进血栓形成,对急性心脑血管疾病病情进展及预后具有重要影响。 PAI-1除了抑制纤溶,促进血栓形成外,还参与动脉粥样硬化的发生发展过程,一方面通过促进纤维蛋白在局部沉积,为细胞黏附,迁移和增殖提供必要基质,另一方面参与调节细胞增殖、迁移、粘附及凋亡,细胞外基质产生与降解等多种过程。
纖溶功能減低是血液高緻栓性的一箇重要組成部分,常見于急性冠脈綜閤徵患者,尤以纖溶酶原激活物抑製物(plasminogen activator inhibitor-1,PAI-1)水平升高為著。 PAI-1通過抑製纖維溶解,促進血栓形成,對急性心腦血管疾病病情進展及預後具有重要影響。 PAI-1除瞭抑製纖溶,促進血栓形成外,還參與動脈粥樣硬化的髮生髮展過程,一方麵通過促進纖維蛋白在跼部沉積,為細胞黏附,遷移和增殖提供必要基質,另一方麵參與調節細胞增殖、遷移、粘附及凋亡,細胞外基質產生與降解等多種過程。
섬용공능감저시혈액고치전성적일개중요조성부분,상견우급성관맥종합정환자,우이섬용매원격활물억제물(plasminogen activator inhibitor-1,PAI-1)수평승고위저。 PAI-1통과억제섬유용해,촉진혈전형성,대급성심뇌혈관질병병정진전급예후구유중요영향。 PAI-1제료억제섬용,촉진혈전형성외,환삼여동맥죽양경화적발생발전과정,일방면통과촉진섬유단백재국부침적,위세포점부,천이화증식제공필요기질,령일방면삼여조절세포증식、천이、점부급조망,세포외기질산생여강해등다충과정。
Fibrinolytic dysfunction, especially the elevated level of plasminogen activator inhibitor (PAI-1), is an im-portant part of blood thrombogenecity which is common in patients with acute coronary syndrome. PAI-1 has an im-portant influence on the progress and prognosis of acute cerebrovascular disease by inhibiting fibrinolysis and promot-ing thrombus formation. In addition to play an important role in the occurrence of atherothrombosis, PAI-1 might be involved in atherosclerosis. On the one hand, PAI-1 inhibits fibrinolysis and promotes fibrin in the local area, which provides the necessary matrix for cell adhesion, migration and proliferation. On the other hand, PAI-1 is also involved in the regulation of cell proliferation, migration, adhesion and apoptosis, as well as the production and degradation of extracellular matrix.
